WORLDWIDE PREVALENCE OF ?-HCV

13.09.00

Click here to start

Table of Contents

  1. WORLDWIDE PREVALENCE OF anti-HCV
  2. The hepatitis C virus
  3. HEPATITIS C WIEVIELE SCHWEIZER SIND BETROFFEN?
  4. Risk factors for acquisition of hepatitis C
  5. Infection with HIV and HCV in i.v. drug users.
  6. Lack of sexual transmission of hepatitis C
  7. Mother to child transmission of HCV
  8. Persistence and progression of vertically acquired hepatitisS
  9. eroconversion rate and persistance of viremia in acute hepatitis C
  10. Loss of HCV-RNA or normalization of transaminases in CHC
  11. PROGRESSION OF FIBROSIS IN CHRONIC HEPATITIS C
  12. Probability of transition to cirrhosis in CHC
  13. Survival without complications as a function of hyaluronate in compensated HCV cirrhosis
  14. Natural history of hepatitis C in young women
  15. MORBIDITY AND MORTALITY IN COMPENSATED CIRRHOSIS TYPE C
  16. Effect of alcohol consumption on hepatitis C
  17. Effect of alcohol consumption on hepatitis C
  18. BERATUNG DES PATIENTEN MIT HEPATITIS C
  19. Symptoms in patients with hepatitis C
  20. Quality of life in chronic hepatitis
  21. QUALITY OF LIFE IS MARKEDLY IMPAIRED IN CHRONIC HEPATITIS
  22. Tests für Hepatitis C
  23. SASL V: RELATIONSHIP BETWEEN HISTOLOGIC AND BIOCHEMICAL SEVERITY
  24. SASL V: RELATIONSHIP BETWEEN GEC AND HISTOLOGIC SEVERITY
  25. Hepatitis C: Grading
  26. Hepatitis C: Staging
  27. LIVER BIOPSY IN a-HCV POSITIVE PATIENTS WITH NORMAL TRANSAMINASES
  28. Histology in patients with hepatitis C
  29. DEFINITIONEN IN DER BEHANDLUNG DER CHRONISCHEN HEPATITIS C
  30. META-ANALYSIS OF INTERFERON TRIALS IN CHRONIC HEPATITIS C
  31. META-ANALYSIS OF TRIALS OF INTERFERONa IN CHRONIC HEPATITIS C
  32. PREDICTORS OF RESPONSE TO INTERFERONa IN CHRONIC HEPATITIS C
  33. CUMULATIVE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN TREATED CIRRHOTIC HEPATITIS C
  34. EFFECT OF a-INTERFERON ON DEVELOPMENT OF HEPATOCELLULAR CANCER IN HEPATITIS C
  35. EFFECT OF a-INTERFERON ON HEPATIC DECOMPENSATION IN CHRONIC HEPATITIS C
  36. BIOCHEMICAL, VIROLOGICAL AND HISTOLOGICAL RESPONSE IN CHC
  37. Modelling the impact of interferon on progression of fibrosis in chronic hepatitis C
  38. Effect of treatment on quality of life in CHC
  39. META-ANALYSIS OF TREATMENT OF ACUTE HEPATITIS C
  40. COMBINATION TREATMENT OF HEPATITIS C SUSTAINED VIROLOGICAL RESPONSE
  41. Sustained response in chronic hepatitis C induced by combination treatment Results of the U.S. and International trial
  42. Sustained response in CHC according to genotype (48 weeks of treatment) Results of the U.S. and International trial
  43. Interferon + ribavirin in patients with CHC relapsing after monotherapy
  44. Sustained virological response in chronic hepatitis C
  45. Efficacy of pegylated interferon-a2a (40 kD)
  46. Comparison of two pegylated interferons Zeuzem (40 kD) and Trépo (12 kD)
  47. Markov model to evaluate strategies in the treatment of chronic hepatitis C
  48. FUTURE TREATMENT OF HEPATITIS C
  49. Iron reduction (IRT) therapy in CHC
  50. AUTOIMMUNITY IN HEPATITIS C
  51. HCV behaves as an opportunistic infection in HIV-positive patients
  52. Impact of hepatitis C on survival in renal transplantation
  53. Non-Hodgkin lymphoma in chronic hepatitis
  54. Diabetes mellitus and hepatitis
  55. Porphyria cutanea tarda and hepatitis C
  56. Outcome of OLT for hepatitis C
 Author: Department of Clinical Pharmacology 

Email: reichen@ikp.unibe.ch

Home Page: http://www.ikp.unibe.ch/lab2/